结直肠癌治疗研究进展
Research Progress in the Treatment of Colorectal Cancer
DOI: 10.12677/acm.2024.1441006, PDF,   
作者: 曼尼哈·达吾力*, 唐 勇#：新疆医科大学第三临床医学院，新疆 乌鲁木齐
关键词: 结直肠癌；化疗；靶向治疗；微卫星标记；免疫治疗；Colorectal Cancer； Chemotherapy； Targeted Therapy； Microsatellite； Immunotherapy
摘要: 根据国际癌症研究机构数据，结直肠癌是世界第三大常见癌症，也是导致癌症相关死亡的第二大原因，在全球范围内具有高发病率。本文就早期可切除结直肠癌、初始可切除性转移性结直肠癌的局部治疗及初始不可切除转移性结直肠癌的全身治疗完成综述。尽管结肠镜检查等早期筛查技术取得了进步，提高了患者的生存率，但或因此项为侵入性检查原因，仍有相当数量的患者贻误了诊治实际，在晚期才得到诊断，所以重点针对转移性结直肠癌患者的局部及全身治疗进行了阐述。
Abstract: According to the International Agency for Research on Cancer reports, colorectal cancer is the third most prevalent form of cancer in the world and the second leading cause of cancer-related mortality, the global prevalence of this condition is significantly high. This article reviews the local treatment of early resectable colorectal cancer, initial resectable metastatic colorectal cancer, and systemic treatment of initial unresectable metastatic colorectal cancer. Although early screening techniques such as colonoscopy have made progress and improved the survival rate of patients, there are still a considerable number of patients who are delayed in diagnosis and treatment and are diagnosed at a late stage because of invasive examination. Therefore, the local and systemic treatment of patients with metastatic colorectal cancer is mainly discussed.
文章引用：曼尼哈·达吾力, 唐勇. 结直肠癌治疗研究进展[J]. 临床医学进展, 2024, 14(4): 198-203. https://doi.org/10.12677/acm.2024.1441006

参考文献

[1] Kelly, M.E., Spolverato, G., Le, G., Mavros, M.N., Doyle, F., Pawlik, T.M. and Winter, D.C. (2014) Synchronous Colorectal Liver Metastasis: A Network Meta-Analysis Review Comparing Classical, Combined, and Liver-First Surgical Strategies. Journal of Surgical Oncology, 111, 341-351. [Google Scholar] [CrossRef] [PubMed]
[2] Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. [Google Scholar] [CrossRef] [PubMed]
[3] Conroy, T., Borg, C., et al. (2021) Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 702-715.
[4] Vulasala, S.S.R., Sutphin, P.D., Kethu, S., Onteddu, N.K. and Kalva, S.P. (2023) Interventional Radiological Therapies in Colorectal Hepatic Metastases. Frontiers in Oncology, 13, Arti963966. [Google Scholar] [CrossRef] [PubMed]
[5] Ma, B., Gao, P., Wang, H., Xu, Q., Song, Y., Huang, X., Sun, J., Zhao, J., Luo, J., Sun, Y. and Wang, Z. (2017) What Has Preoperative Radio(Chemo)Therapy Brought to Localized Rectal Cancer Patients in Terms of Perioperative and Long-Term Outcomes over the Past Decades? A Systematic Review and Meta-Analysis Based on 41,121 Patients. International Journal of Cancer, 141, 1052-1065. [Google Scholar] [CrossRef] [PubMed]
[6] Van Tilborg, A.A.J.M., Meijerink, M.R., Sietses, C., Van Waesberghe, J.H.T.M., Mackintosh, M.O., Meijer, S., Van Kuijk, C. and Van Den Tol, P. (2011) Long-Term Results of Radiofrequency Ablation for Unresectable Colorectal Liver Metastases: A Potentially Curative Intervention. British Journal of Radiology, 84, 556-565. [Google Scholar] [CrossRef] [PubMed]
[7] Zacharakis, M., Xynos, I.D., Lazaris, A., et al. (2010) Predictors of Survival in Stage IV Metastatic Colorectal Cancer. Anticancer Research, 30, 653-660.
[8] Heinemann, V., Von Weikersthal, L.F., Decker, T., et al. (2014) FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 1065-1075. [Google Scholar] [CrossRef] 
[9] Yoshino, T., Watanabe, J., Shitara, K., et al. (2022) Panitumumab (PAN) plus MFOLFOX6 versus Bevacizumab (BEV) plus MFOLFOX6 as First-Line Treatment in Patients with RAS Wild-Type (WT) Metastatic Colorectal Cancer (MCRC): Results from the Phase 3 PARADIGM Trial. JCO, 40, LBA1. [Google Scholar] [CrossRef] 
[10] Denda, T., Sakai, D., Hamaguchi, T., et al. (2019) Phase II Trial of Aflibercept with FOLFIRI as a Second-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer. Cancer Science, 110, 1032-1043. [Google Scholar] [CrossRef] [PubMed]
[11] Tampellini, M., Sonetto, C. and Scagliotti, G.V. (2016) Novel Anti-Angiogenic Therapeutic Strategies in Colorectal Cancer. Expert Opinion on Investigational Drugs, 25, 507-520. [Google Scholar] [CrossRef] [PubMed]
[12] Wilhelm, S.M., Dumas, J., Adnane, L., Lynch, M., Carter, C.A., Schütz, G., Thierauch, K.-H. and Zopf, D. (2011) Regorafenib (BAY 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. International Journal of Cancer, 129, 245-255. [Google Scholar] [CrossRef] [PubMed]
[13] Grothey, A., Van Cutsem, E., Sobrero, A., et al. (2013) Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 303-312. [Google Scholar] [CrossRef] 
[14] Burki, T.K. (2018) Fruquintinib for Previously Treated Metastatic Colorectal Cancer. The Lancet Oncology, 19, e388. [Google Scholar] [CrossRef] 
[15] Li, J., Qin, S., Xu, R., et al. (2018) Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA, 319, 2486-2496. [Google Scholar] [CrossRef] [PubMed]
[16] Venook, A.P., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O’Neil, B.H. and Lenz, H.-J. (2016) Impact of Primary (1˚) Tumor Location on Overall Survival (OS) and Progression-Free Survival (PFS) in Patients (Pts) with Metastatic Colorectal Cancer (MCRC): Analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 34, 3504-3504. [Google Scholar] [CrossRef] 
[17] Peeters, M., Price, T.J., Cervantes, A., et al. (2014) Final Results from a Randomized Phase 3 Study of FOLFIRI ± Panitumumab for Second-Line Treatment of Metastatic Colorectal Cancer. Annals of Oncology, 25, 107-116. [Google Scholar] [CrossRef] [PubMed]
[18] Strickler, J.H., Van Cutsem, E., et al. (2023) Tucatinib plus Trastuzumab for Chemotherapy-Refractory, HER2-Positive, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER): A Multicentre, Open-Label, Phase 2 Study. The Lancet Oncology, 24, 496-508.
[19] Ciombor, K.K., Strickler, J.H., Bekaii-Saab, T.S., et al. (2022) BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. JCO, 40, 2706-2715. [Google Scholar] [CrossRef] 
[20] Marabelle, A., Le, D.T., Ascierto, P.A., et al. (2020) Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. JCO, 38, 1-10. [Google Scholar] [CrossRef] 
[21] Maio, M., Ascierto, P.A., Manzyuk, L., et al. (2021) Pembrolizumab in Microsatellite Instability High (MSI-H)/Mismatch Repair Deficient (DMMR) Cancers: Updated Analysis from Phase 2 KEYNOTE-158 Study. JCO, 39, 2565-2565. [Google Scholar] [CrossRef] 
[22] Overman, M.J., Lonardi, S., Wong, K.Y.M., et al. (2018) Durable Clinical Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. JCO, 36, 773-779. [Google Scholar] [CrossRef] 

为你推荐